Search Results - "YELENSKY, Roman"

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies by Lipson, Doron, Capelletti, Marzia, Yelensky, Roman, Otto, Geoff, Parker, Alex, Jarosz, Mirna, Curran, John A, Balasubramanian, Sohail, Bloom, Troy, Brennan, Kristina W, Donahue, Amy, Downing, Sean R, Frampton, Garrett M, Garcia, Lazaro, Juhn, Frank, Mitchell, Kathy C, White, Emily, White, Jared, Zwirko, Zac, Peretz, Tamar, Nechushtan, Hovav, Soussan-Gutman, Lior, Kim, Jhingook, Sasaki, Hidefumi, Kim, Hyeong Ryul, Park, Seung-il, Ercan, Dalia, Sheehan, Christine E, Ross, Jeffrey S, Cronin, Maureen T, Jänne, Pasi A, Stephens, Philip J

“…Using high-coverage targeted next-generation sequencing, this report provides a catalog of genetic alterations in colorectal and lung cancers, identifying…”
Get full text

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial by Swisher, Elizabeth M, Dr Prof, Lin, Kevin K, PhD, Oza, Amit M, Prof, Scott, Clare L, PhD, Giordano, Heidi, MA, Sun, James, PhD, Konecny, Gottfried E, MD, Coleman, Robert L, Prof, Tinker, Anna V, MD, O'Malley, David M, MD, Kristeleit, Rebecca S, MD, Ma, Ling, MD, Bell-McGuinn, Katherine M, MD, Brenton, James D, Prof, Cragun, Janiel M, MD, Oaknin, Ana, MD, Ray-Coquard, Isabelle, Prof, Harrell, Maria I, PhD, Mann, Elaina, MS, Kaufmann, Scott H, Prof, Floquet, Anne, MD, Leary, Alexandra, MD, Harding, Thomas C, PhD, Goble, Sandra, MS, Maloney, Lara, BA, Isaacson, Jeff, PhD, Allen, Andrew R, MD, Rolfe, Lindsey, MBChB, Yelensky, Roman, PhD, Raponi, Mitch, PhD, McNeish, Iain A, Prof

“…Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1…”
Get full text

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing by Frampton, Garrett M, Fichtenholtz, Alex, Otto, Geoff A, Wang, Kai, Downing, Sean R, He, Jie, Schnall-Levin, Michael, White, Jared, Sanford, Eric M, An, Peter, Sun, James, Juhn, Frank, Brennan, Kristina, Iwanik, Kiel, Maillet, Ashley, Buell, Jamie, White, Emily, Zhao, Mandy, Balasubramanian, Sohail, Terzic, Selmira, Richards, Tina, Banning, Vera, Garcia, Lazaro, Mahoney, Kristen, Zwirko, Zac, Donahue, Amy, Beltran, Himisha, Mosquera, Juan Miguel, Rubin, Mark A, Dogan, Snjezana, Hedvat, Cyrus V, Berger, Michael F, Pusztai, Lajos, Lechner, Matthias, Boshoff, Chris, Jarosz, Mirna, Vietz, Christine, Parker, Alex, Miller, Vincent A, Ross, Jeffrey S, Curran, John, Cronin, Maureen T, Stephens, Philip J, Lipson, Doron, Yelensky, Roman

“…Clinical tests that rely on next-generation sequencing to evaluate large numbers of cancer genes can be validated using pooled cell lines with known mutations…”
Get full text

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal by Sun, James X, He, Yuting, Sanford, Eric, Montesion, Meagan, Frampton, Garrett M, Vignot, Stéphane, Soria, Jean-Charles, Ross, Jeffrey S, Miller, Vincent A, Stephens, Phil J, Lipson, Doron, Yelensky, Roman

“…A key constraint in genomic testing in oncology is that matched normal specimens are not commonly obtained in clinical practice. Thus, while well-characterized…”
Get full text

Estimation of the multiple testing burden for genomewide association studies of nearly all common variants by Pe'er, Itsik, Yelensky, Roman, Altshuler, David, Daly, Mark J.

“…Genomewide association studies are an exciting strategy in genetics, recently becoming feasible and harvesting many novel genes linked to multiple phenotypes…”
Get full text

The distribution of BRAF gene fusions in solid tumors and response to targeted therapy by Ross, Jeffrey S., Wang, Kai, Chmielecki, Juliann, Gay, Laurie, Johnson, Adrienne, Chudnovsky, Jacob, Yelensky, Roman, Lipson, Doron, Ali, Siraj M, Elvin, Julia A., Vergilio, Jo‐Anne, Roels, Steven, Miller, Vincent A, Nakamura, Brooke N., Gray, Adam, Wong, Michael K, Stephens, Philip J

“…Although the BRAF V600E base substitution is an approved target for the BRAF inhibitors in melanoma, BRAF gene fusions have not been investigated as anticancer…”
Get full text

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study by Wheler, Jennifer J, Janku, Filip, Naing, Aung, Li, Yali, Stephen, Bettzy, Zinner, Ralph, Subbiah, Vivek, Fu, Siqing, Karp, Daniel, Falchook, Gerald S, Tsimberidou, Apostolia M, Piha-Paul, Sarina, Anderson, Roosevelt, Ke, Danxia, Miller, Vincent, Yelensky, Roman, Lee, J Jack, Hong, David S, Kurzrock, Razelle

“…Innovative molecular diagnostics deployed in the clinic enable new ways to stratify patients into appropriate treatment regimens. These approaches may resolve…”
Get full text

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors by Frampton, Garrett M, Ali, Siraj M, Rosenzweig, Mark, Chmielecki, Juliann, Lu, Xinyuan, Bauer, Todd M, Akimov, Mikhail, Bufill, Jose A, Lee, Carrie, Jentz, David, Hoover, Rick, Ou, Sai-Hong Ignatius, Salgia, Ravi, Brennan, Tim, Chalmers, Zachary R, Jaeger, Savina, Huang, Alan, Elvin, Julia A, Erlich, Rachel, Fichtenholtz, Alex, Gowen, Kyle A, Greenbowe, Joel, Johnson, Adrienne, Khaira, Depinder, McMahon, Caitlin, Sanford, Eric M, Roels, Steven, White, Jared, Greshock, Joel, Schlegel, Robert, Lipson, Doron, Yelensky, Roman, Morosini, Deborah, Ross, Jeffrey S, Collisson, Eric, Peters, Malte, Stephens, Philip J, Miller, Vincent A

“…Focal amplification and activating point mutation of the MET gene are well-characterized oncogenic drivers that confer susceptibility to targeted MET…”
Get more information

Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity by Beltran, Himisha, Yelensky, Roman, Frampton, Garrett M, Park, Kyung, Downing, Sean R, MacDonald, Theresa Y, Jarosz, Mirna, Lipson, Doron, Tagawa, Scott T, Nanus, David M, Stephens, Philip J, Mosquera, Juan Miguel, Cronin, Maureen T, Rubin, Mark A

“…Abstract Background Most personalized cancer care strategies involving DNA sequencing are highly reliant on acquiring sufficient fresh or frozen tissue. It has…”
Get full text

New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next‐Generation Sequencing by Ross, Jeffrey S., Wang, Kai, Gay, Laurie, Al‐Rohil, Rami, Rand, Janne V., Jones, David M., Lee, Hwa J., Sheehan, Christine E., Otto, Geoff A., Palmer, Gary, Yelensky, Roman, Lipson, Doron, Morosini, Deborah, Hawryluk, Matthew, Catenacci, Daniel V. T., Miller, Vincent A., Churi, Chaitanya, Ali, Siraj, Stephens, Philip J.

“…Background. Intrahepatic cholangiocarcinoma (ICC) is a subtype of primary liver cancer that is rarely curable by surgery and is rapidly increasing in…”
Get full text

Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms by Rampal, Raajit, Ahn, Jihae, Abdel-Wahab, Omar, Nahas, Michelle, Wang, Kai, Lipson, Doron, Otto, Geoff A, Yelensky, Roman, Hricik, Todd, McKenney, Anna Sophia, Chiosis, Gabriela, Chung, Young Rock, Pandey, Suveg, van den Brink, Marcel R M, Armstrong, Scott A, Dogan, Ahmet, Intlekofer, Andrew, Manshouri, Taghi, Park, Christopher Y, Verstovsek, Srdan, Rapaport, Franck, Stephens, Philip J, Miller, Vincent A, Levine, Ross L

“…Patients with myeloproliferative neoplasms (MPNs) are at significant, cumulative risk of leukemic transformation to acute myeloid leukemia (AML), which is…”
Get full text

Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib by Wong, Victor, Pavlick, Dean, Brennan, Tim, Yelensky, Roman, Crawford, John, Ross, Jeffrey S, Miller, Vincent A, Malicki, Denise, Stephens, Philip J, Ali, Siraj M, Ahn, Hyunah

Get full text

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 by Herbst, Roy S, Gandara, David R, Hirsch, Fred R, Redman, Mary W, LeBlanc, Michael, Mack, Philip C, Schwartz, Lawrence H, Vokes, Everett, Ramalingam, Suresh S, Bradley, Jeffrey D, Sparks, Dana, Zhou, Yang, Miwa, Crystal, Miller, Vincent A, Yelensky, Roman, Li, Yali, Allen, Jeff D, Sigal, Ellen V, Wholley, David, Sigman, Caroline C, Blumenthal, Gideon M, Malik, Shakun, Kelloff, Gary J, Abrams, Jeffrey S, Blanke, Charles D, Papadimitrakopoulou, Vassiliki A

“…The Lung Master Protocol (Lung-MAP, S1400) is a groundbreaking clinical trial designed to advance the efficient development of targeted therapies for squamous…”
Get full text

Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets by Balko, Justin M, Giltnane, Jennifer M, Wang, Kai, Schwarz, Luis J, Young, Christian D, Cook, Rebecca S, Owens, Phillip, Sanders, Melinda E, Kuba, Maria G, Sánchez, Violeta, Kurupi, Richard, Moore, Preston D, Pinto, Joseph A, Doimi, Franco D, Gómez, Henry, Horiuchi, Dai, Goga, Andrei, Lehmann, Brian D, Bauer, Joshua A, Pietenpol, Jennifer A, Ross, Jeffrey S, Palmer, Gary A, Yelensky, Roman, Cronin, Maureen, Miller, Vincent A, Stephens, Phillip J, Arteaga, Carlos L

“…Neoadjuvant chemotherapy (NAC) induces a pathologic complete response (pCR) in approximately 30% of patients with triple-negative breast cancers (TNBC). In…”
Get more information

Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes by Chmielecki, Juliann, Hutchinson, Katherine E, Frampton, Garrett M, Chalmers, Zachary R, Johnson, Adrienne, Shi, Chanjuan, Elvin, Julia, Ali, Siraj M, Ross, Jeffrey S, Basturk, Olca, Balasubramanian, Sohail, Lipson, Doron, Yelensky, Roman, Pao, William, Miller, Vincent A, Klimstra, David S, Stephens, Philip J

“…Pancreatic acinar cell carcinomas (PACC) account for approximately 1% (∼500 cases) of pancreatic cancer diagnoses annually in the United States. Oncogenic…”
Get more information

Next-Generation Sequencing Reveals High Concordance of Recurrent Somatic Alterations Between Primary Tumor and Metastases From Patients With Non–Small-Cell Lung Cancer by VIGNOT, Stéphane, FRAMPTON, Garrett M, ANDRE, Fabrice, STEPHENS, Philip J, LAZAR, Vladimir, MILLER, Vincent A, BRAMBILLA, Elisabeth, SORIA, Jean-Charles, YELENSKY, Roman, COMMO, Frédéric, BRAMBILLA, Christian, PALMER, Gary, MORO-SIBILOT, Denis, ROSS, Jeffrey S, CRONIN, Maureen T

“…Characterization of the genomic changes that drive an individual patient's disease is critical in management of many cancers. In patients with non-small-cell…”
Get full text

Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations by Ross, Jeffrey S., Wang, Kai, Khaira, Depinder, Ali, Siraj M., Fisher, Huge A.G., Mian, Badar, Nazeer, Tipu, Elvin, Julia A., Palma, Norma, Yelensky, Roman, Lipson, Doron, Miller, Vincent A., Stephens, Philip J., Subbiah, Vivek, Pal, Sumanta K.

“…BACKGROUND In the current study, the authors present a comprehensive genomic profile (CGP)‐based study of advanced urothelial carcinoma (UC) designed to detect…”
Get full text

Efficiency and power in genetic association studies by Daly, Mark J, Altshuler, David, de Bakker, Paul I W, Yelensky, Roman, Pe'er, Itsik, Gabriel, Stacey B

“…We investigated selection and analysis of tag SNPs for genome-wide association studies by specifically examining the relationship between investment in…”
Get full text

Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies by Ross, Jeffrey S., Gay, Laurie M., Wang, Kai, Ali, Siraj M., Chumsri, Saranya, Elvin, Julia A., Bose, Ron, Vergilio, Jo‐Anne, Suh, James, Yelensky, Roman, Lipson, Doron, Chmielecki, Juliann, Waintraub, Stanley, Leyland‐Jones, Brian, Miller, Vincent A., Stephens, Philip J.

“…BACKGROUND Activating, nonamplification ERBB2 mutations (ERBB2mut) are not detected by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH),…”
Get full text

Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets by Lee, Hwajeong, Wang, Kai, Johnson, Adrienne, Jones, David M, Ali, Siraj M, Elvin, Julia A, Yelensky, Roman, Lipson, Doron, Miller, Vincent A, Stephens, Philip J, Javle, Milind, Ross, Jeffrey S

“…We queried whether extrahepatic cholangiocarcinoma featured clinically relevant genomic alterations that could lead to targeted therapy. Comprehensive genomic…”
Get more information